Inotrem raises €39M from Morningside Venture Partners, Andera Partners, Sofinnova Partners and BioMed Partners

Inotrem, a biotech developing immunotherapies targeting the TREM-1 pathway, raises €39M in a Series B led by Morningside, with Andera Partners, Sofinnova Partners and BiomedInvest, to fund a Phase IIb trial in septic shock.